Genzyme GENZ

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. FDA approves new drug for Gaucher's disease

      Headlines

      Tue, 19 Aug 2014

      The FDA clears Genzyme 's ( SNY -0.3% ) Cerdelga (eliglustat) an oral therapy for the ..... fatty materials by inhibiting the metabolic process that forms them. Genzyme 's first drug for Type 1 Gaucher disease was Ceredase ( alglucerase

    2. Second Quarter Results Confirm Why We Like Aastrom

      Headlines

      Tue, 19 Aug 2014

      recently acquired Cell Therapy and Regenerative Medicine (CTRM) business from Sanofi (NYSE: SNY ), previously known as Genzyme Biosurgery Aps. Total revenues for the quarter were approximately $4.4 million, and were comprised of approximately

    3. Aegerion Pharmaceuticals Is Still Significantly Overvalued

      Headlines

      Tue, 19 Aug 2014

      approximately one in a million people in the U.S., according to scientific studies, which made Juxtapid an orphan drug . Genzyme 's Kynamro, which has also been developed to treat HoFH, has also been granted an orphan drug status. Interestingly

    4. Sanofi Appears To Be In The Early Stages Of An Earnings Rebound

      Headlines

      Mon, 11 Aug 2014

      and substantially increased its presence in the lucrative biotechnology arena earlier this decade with the addition of Genzyme , is a diversified powerhouse, with a product portfolio that includes seven blockbusters and dozens of medicines/vaccines

    5. New Morningstar Analyst Report for Biomarin Pharmaceutical Inc

      Stock Reports

      Tue, 5 Aug 2014

      of BioMarin's expertise. Viral contamination forced Genzyme (now Sanofi) to halt manufacturing of its enzyme replacement ..... disease therapies, and three products drive its sales. Genzyme (now part of Sanofi) markets Aldurazyme through its joint

    6. FDA approves Lumizyme label expansion

      Headlines

      Fri, 1 Aug 2014

      The FDA approves the use of Genzyme 's ( SNY +1.7% ) Lumizyme (alglucosidase alfa) for the treatment of patients with infantile-onset Pompe disease who are

    7. New Morningstar Analyst Report for Sanofi

      Stock Reports

      Fri, 14 Mar 2014

      the Medley, Chattem, Merial, and Genzyme acquisitions all have generated returns ..... than four years. Additionally, the Genzyme acquisition shows how Sanofi avoided ..... value rights, or CVR, to appease Genzyme . Further, Viehbacher's decision

    8. ClearBridge Fund Prepared for Extended Rally

      Video Reports

      Fri, 11 Oct 2013

      continues. I think there is going to be a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase

      Genzyme found at 3:20

      a theme, which we've seen in our portfolio, where historically names like Genzyme , Chiron, Millennium, and ImClone have all been acquired, and what we're seeing today is Big Pharma continue to chase growth and do
    9. Invest With These Exemplary Management Teams

      Headlines

      Sun, 26 May 2013

      the Medley, Chattem, Merial, and Genzyme acquisitions all have generated returns ..... than four years. Additionally, the Genzyme acquisition shows how Sanofi avoided ..... value rights, or CVR, to appease Genzyme . Further, Viehbacher's decision

    10. Sanofi's 4Q and 2013 Guidance Match Our Projections but Fall Short of Consensus Expectations

      Commentary

      Thu, 7 Feb 2013

      quarterly results. The company's updated guidance on an improving pipeline along with steady growth from emerging markets, Genzyme products, consumer health, vaccines, and diabetes drugs increases our conviction behind our wide moat rating for the

    « Prev12345Next »
    Content Partners